Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM
Details : Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during th...
Brand Name : Cetrorelix Acetate-Generic
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 27, 2022
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akorn Announces FDA-Approved Generic Cetrorelix Acetate for Injection 0.25 mg
Details : Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.
Brand Name : Cetrorelix Acetate-Generic
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 16, 2022
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Théa Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Akorn Announces Completion of the Sale of its Branded Ophthalmic Products to Théa Pharma
Details : Under the deal, Théa Pharma acquired seven products including established glaucoma therapies Zioptan®, Cosopt®, Cosopt® PF, and Betimol®, along with Azasite®, Akten®, and the ocular surface repair agent AcellFX™.
Brand Name : Zioptan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2022
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Théa Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Laboratoires Thea
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growt...
Brand Name : Zioptan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 28, 2022
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Laboratoires Thea
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Prestige Consumer Healthcare
Deal Size : $230.0 million
Deal Type : Divestment
Akorn Announces Agreement to Sell its Consumer Health Business to Prestige Consumer Healthcare
Details : The Consumer Health business primarily consists of the following over-the-counter brands: TheraTears , Diabetic Tussin , MagOx , Multi-betic , and Zostrix.
Brand Name : TheraTears
Molecule Type : Small molecule
Upfront Cash : $230.0 million
May 27, 2021
Lead Product(s) : Sodium Carboxymethylcellulose
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Prestige Consumer Healthcare
Deal Size : $230.0 million
Deal Type : Divestment
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
Details : Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 11, 2021
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?